Navigation Links
Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications
Date:3/12/2013

NEWTON, Mass., March 12, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, announced today that it has entered into an exclusive license agreement with the University of Bristol.  Under the terms of the agreement, the Company has acquired exclusive worldwide rights to use, for all skin applications, a novel method to manufacture a class of prostaglandins that reduces fat.  Additional terms were not disclosed. 

The revolutionary technology, which one expert has called "unbeatable in its conciseness and elegance", greatly simplifies synthesis of prostaglandins.  It is expected to improve manufacturing efficiency by 5-10 fold and substantially reduce manufacturing costs.  The technology, featured in the September 13th, 2012 issue of Nature magazine, was developed at the University of Bristol by Professor Varinder Aggarwal and colleagues.

"There is remarkable synergy between our research and Topokine's innovative products.  I look forward to helping advance Topokine's efforts by applying our synthesis technology," said Professor Aggarwal, a Fellow of the Royal Society who has joined Topokine's Advisory Board.

"Professor Aggarwal's group is at the cutting-edge of prostaglandin chemistry," said Murat Kalayoglu, MD, PhD, Topokine President & CEO.  "This exclusive license further enhances our IP position, and we are excited to collaborate with him and the University of Bristol."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat.  XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors.  XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

About the University of Bristol

The University of Bristol is consistently ranked among the leaders in UK higher education.  Research-intensive and with an international reputation for quality and innovation, the University has over 18,000 students from over 100 countries, together with more than 5,000 staff.  Places at Bristol are among the most highly sought after of all UK universities.  The University was founded in 1876 and was granted its Royal Charter in 1909.  It was the first university in England to admit women on the same basis as men.  It is located in the heart of the city from which it grew, but is now a significant player on the world stage as well as a major force in the economic, social and cultural life of Bristol and South West England.  Bristol is a member of the Worldwide Universities Network and of the Russell Group of leading research-intensive universities in the UK.

Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc., murat.kalayoglu@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
2. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
3. Shire Acquires Premacure AB
4. BD Acquires Cato Software Solutions
5. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
6. Dynamic Healthcare Services Acquires the operating assets of APO2, a Provider of Home Medical Equipment and Respiratory Therapy Products and Services in Hazleton, PA
7. PRA Acquires ClinStar
8. Endexx Acquires Medical Marijuana Management Technology
9. DSI Renal Acquires New Smyrna Beach Artificial Kidney Center
10. Henry Schein Acquires The Maddox Practice Group
11. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Gamida Cell, a leader in ... and orphan genetic diseases, announced today it has been ... the Israel Innovation Authority (formerly the Office of the ... Industry. The mission of the Israel Innovation Authority is ... science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... , May 23, 2016 ... develop its anti-fibrotic and anti-inflammatory compound DS102 in ... as in non-alcoholic steatohepatitis (NASH) patients. ... significantly sequestered in lung tissue and has bronchodilatory, ... after oral administration. The Company will publish further ...
(Date:5/20/2016)... LONDON , May 20, 2016 ... for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant ... Emerging Biological Drugs - This New Study Reveals ... Stay Ahead ,What is the ... get the latest technological and commercial analysis. Staying ...
Breaking Medicine Technology:
(Date:5/25/2016)... , ... May 25, 2016 , ... ... has announced that it will join America's leading engineers at the American Society ... at the Georgia World Congress Center. , Engineers, speakers and exhibitors from ...
(Date:5/24/2016)... ... May 24, 2016 , ... BTC Media, a leading ... Distributed: Health, to be held in Nashville, Tennessee on September 7, 2016. , ... Hackathon preceding the event will host teams from around the world, competing to ...
(Date:5/24/2016)... Santa Rosa, California (PRWEB) , ... May 24, ... ... management (PHM) technology, debuted a new corporate identity and website at its “Transforming ... brand, website, and other marketing enhancements reflect i2i’s ongoing success to set the ...
(Date:5/24/2016)... ... May 24, 2016 , ... Local engineering ... Northern Virginia Medical Center located in Woodbridge, VA. The project includes a ... a single site. , The new 2 story building houses the Central Sterile ...
(Date:5/24/2016)... CA — , ... ... appointment of three new members of its Advisory Board. Joining ... and Sarah Kusch. “All three of them embody the mission of ... We are very fortunate to have them as we continue to ...
Breaking Medicine News(10 mins):